Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox plus Azacitidine in Higher Risk MDS
NCT02038816Phase 2Terminated
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Mar 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deferasirox in myelodysplastic syndrome (MDS), sponsored by Sunnybrook Health Sciences Centre. Started Mar 2014; status: terminated.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02038816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038816.